MedTrace Logo

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

NCT00035945 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-12-05

No results posted yet for this study

Summary

Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

ISIS 14803

Sponsors & Collaborators

  • Hepasense

    collaborator INDUSTRY

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-01
Primary Completion
2004-05-01
Completion
2004-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00035945 on ClinicalTrials.gov